-
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Monday, December 4, 2023 - 5:20pm | 703How important it is to have the latest blockbuster in your product portfolio. The pharmaceuticals industry has displayed this over and again in recent years — getting a Covid vaccine to market during the pandemic, and now tackling the obesity epidemic. Those with obesity drugs already on the market...
-
Canadian Study Reveals Link Between Heavy Cannabis Use And Increased Risk Of Heart Problems
Friday, September 29, 2023 - 9:02pm | 502A new study based on medical data from Alberta, Canada, has revealed a connection between cannabis use disorder and an increased risk of cardiovascular issues. Published in Addiction, this research analyzed data from nearly 60,000 adults from 2012 to 2019. Published in Addiction...
-
These Three New Markets May Propel Novo Nordisk's Ozempic To Greater Heights
Friday, August 25, 2023 - 3:08am | 507Novo Nordisk’s (NYSE:NVO) popular semaglutide drugs, Wegovy and Ozempic, may unlock three potential new markets, potentially boosting the company’s fortunes, The Motley Fool reported. Over the past year, Novo Nordisk‘s shares have surged 79%, largely due to the success of its...
-
Is It Safe For Older People To Take Psychedelics? Here's What The Research Says
Friday, June 2, 2023 - 3:17pm | 986This article was originally published on Psychedelic Spotlight and appears here with permission. A new study sheds light on whether psychedelics can safely be used by older adults, revealing previously unknown safety profiles and efficacy of psychedelics for older people, and challenging...
-
Pfizer Posts Vupanorsen Data From Mid-Stage Cardiovascular Disease Trial
Wednesday, November 24, 2021 - 10:57am | 260Pfizer Inc (NYSE: PFE) has provided an update on the Phase 2b study of vupanorsen, investigational antisense therapy for cardiovascular (CV) risk reduction and severe hypertriglyceridemia. In the dose-ranging study in subjects with elevated non-HDL-C and triglycerides (TG), the study met...
-
Milestone Pharma-Ji Xing Pharma Ink $127M Etripamil Development Agreement For China
Monday, May 17, 2021 - 1:22pm | 311Milestone Pharmaceuticals Inc (NASDAQ: MIST) hit a major snag last March when its investigational etripamil nasal spray for episodes of rapid heart rate missed the primary endpoint. A year later, it’s touting new data on its secondary endpoints and a partnership...
-
Cytokinetics Post-Hoc Data Suggests Omecamtiv Mecarbil Works Better In High-Risk Patients For Heart Failure
Monday, May 17, 2021 - 1:02pm | 358Cytokinetics Incorporated (NASDAQ: CYTK) announced secondary data analysis from the GALACTIC-HF trial evaluating omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF). Data were presented at the American College of Cardiology’s Annual...
-
Novartis' Entresto Misses Primary Endpoint In Study After Heart Attacks
Monday, May 17, 2021 - 12:41pm | 409Novartis AG (NYSE: NVS) revealed details on Phase 3 PARADISE-MI trial evaluating Entresto (sacubitril/valsartan) compared with ramipril in a contemporary acute myocardial infarction (AMI) population. Data were presented at the American College of Cardiology's virtual...
-
AstraZeneca's MEDI5884-PCSK9 Inhibitor Combo Shows Promise In Heart Disease
Thursday, April 22, 2021 - 6:56am | 365Most heart disease drugs are aimed at reducing the "bad" low-density lipoprotein (LDL) cholesterol. However, strategies related to cutting LDL cholesterol and increasing high-density lipoprotein (HDL) cholesterol are of interest in combating the risk of heart disease. HDL cholesterol is...
-
CytoSorbents To Start US Study With CytoSorb For Ticagrelor Removal
Monday, April 19, 2021 - 12:22pm | 352The FDA has signed off conditional approval for the STAR-T study to assess CytoSorbents Corporation's (NASDAQ: CTSO) blood purification device, CytoSorb, to remove Ticagrelor. The company can now initiate clinical trial agreement negotiations and institutional review...
-
Amarin Stock Is Trading Higher After EU Approval For Icosapent Ethyl
Tuesday, March 30, 2021 - 7:16am | 221The European Commission (EC) has approved the marketing authorization application for Amarin Corporation Plc's (NASDAQ: AMRN) Vazkepa (icosapent ethyl) for cardiovascular risk reduction. The approval covers reducing the risk of cardiovascular events in high-risk,...
-
Amarin's Vascepa Recommended By Canadian Cardiovascular Society For Prevention Of Cardiovascular Diseases
Monday, March 29, 2021 - 7:28am | 260HLS Therapeutics Inc announced the Canadian Cardiovascular Society had included icosapent ethyl (Vascepa) in 2021 Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults, published in the Canadian Journal of Cardiology. HLS in-licensed the...
-
Cannabis Use Is Not Associated With Increased Risk Of Cardiovascular Disease
Friday, January 29, 2021 - 3:11pm | 633This article by Chynna Pearson was originally published on Cannabis & Tech Today, and appears here with permission. Cardiovascular disease is a major health issue around the globe. In fact, it’s responsible for more annual deaths around the world than any other disease. According to...
-
Amarin Reports Encouraging Data, Vascepa Shows 30% Reduction In Total Cardiovascular Events In REDUCE-IT Study
Monday, March 18, 2019 - 1:27pm | 466Amarin Corporation (NASDAQ: AMRN) presented data for its cardiovascular outcome study of its prescription Vascepa (icosapent ethyl), the REDUCE-IT study. Vascepa demonstrated a statistically significant 30 percent risk reduction in cardiovascular events compared to placebo in the statin-treated...